This article is for general information only and is not a substitute for professional medical advice. Do not stop, start, or change any medication based on what you read here. See our full medical disclaimer.

GLP-1 receptor agonists produce some of the largest sustained weight losses ever recorded in pharmaceutical trials. A question that follows many patients: how much of that lost weight is fat, and how much is the muscle needed for strength, metabolism, and long-term health?

The direct answer: GLP-1 drugs do cause some lean mass loss. The STEP 1 body composition substudy using DEXA found that total lean body mass fell about 9.7 percent in absolute terms over 68 weeks on semaglutide 2.4 mg weekly, while fat mass fell at 19.3 percent. The drugs do not selectively attack muscle, but losing lean tissue on top of age-related decline can push some people closer to functional problems.

Key Takeaways

  • In the STEP 1 DEXA substudy, semaglutide users lost 5.26 kg of lean mass alongside 8.36 kg of fat mass over 68 weeks.
  • A 2024 review found lean mass accounts for roughly 25 to 40 percent of total weight lost across GLP-1 trials.
  • Body composition ratios still improve because fat loss outpaces lean loss, but absolute muscle loss is real.
  • Older adults, women, and people with low protein intake face the highest risk of clinically significant muscle loss.
  • Resistance training two to three times per week plus at least 1.2 g protein per kg body weight per day are the two best-supported countermeasures.
  • The Phase 2b BELIEVE trial showed bimagrumab plus semaglutide achieved 92.8 percent fat-only weight loss, though this combination is not yet approved.

What the STEP Trials Found About Body Composition

The STEP 1 exploratory DEXA substudy followed 1,961 adults randomized to subcutaneous semaglutide 2.4 mg once weekly or placebo for 68 weeks. Participants on semaglutide lost 15.0 percent of body weight versus 3.6 percent on placebo. The semaglutide group lost 8.36 kg of fat mass and 5.26 kg of lean mass; the placebo group lost 1.37 kg of fat and 1.83 kg of lean mass.

The lean-to-fat ratio actually improved with semaglutide: it rose by 0.23 from a baseline of 1.34. Among participants who lost at least 15 percent of body weight, that ratio improved by 0.41. The body composition shift was favorable even though some muscle was lost in absolute terms. The SEMALEAN study added a useful data point: lean mass declined about 3 kg by month 7 then stabilized through month 12, while fat mass kept falling.

Why “Lean Mass” on a DEXA Scan Is Not the Same as Muscle

One detail gets lost in most headlines about these numbers. On a DEXA scan, “lean mass” is not a pure muscle reading. It is everything in the body that is not fat and not bone mineral: skeletal muscle, yes, but also organs, connective tissue, and the water held inside all of it. Skeletal muscle is only about a third of total lean mass. That matters because a meaningful share of the lean mass that vanishes in the first weeks of rapid weight loss is water and stored glycogen, not contractile muscle fiber. Glycogen binds roughly 3 grams of water for every gram it stores, so when you eat far less, glycogen stores shrink and the attached water leaves. On the scan it reads as lean mass loss even though no muscle protein was broken down.

This is one reason early lean mass figures can look alarming and then settle, which is exactly the pattern the SEMALEAN study captured: a drop by month 7 followed by a plateau while fat kept falling. It also explains why a single lean mass percentage is a weaker guide than most people assume. What actually protects your independence and metabolism is functional muscle, so grip strength and how you move under load tell you more than one line on a body composition printout.

How GLP-1 Muscle Loss Compares to Regular Dieting

GLP-1 medications do not do anything uniquely destructive to muscle. Every caloric deficit causes some lean tissue loss. The standard benchmark in the weight loss literature is that roughly 20 to 30 percent of weight lost through diet-only interventions comes from lean tissue. A 2024 review and meta-analysis in Diabetes, Obesity and Metabolism found GLP-1 receptor agonists reduced lean mass by approximately 25 percent relative to total weight lost, with individual study figures ranging from 15 to 40 percent depending on age, exercise habits, and protein intake.

What distinguishes GLP-1 therapy is scale. These drugs achieve 15 to 22 percent body weight reductions that previously required bariatric surgery. A person losing 30 pounds on semaglutide might lose 7 to 12 pounds of that from lean mass. The percentage breakdown is comparable to conventional dieting; the absolute amount is larger because the total loss is larger. For a full picture of how these medications work, see our explainer on GLP-1 medications.

There is also a pace effect. GLP-1 drugs can drive fast early weight loss, and quicker loss tends to pull a larger fraction from lean tissue than slow, gradual loss does. The appetite suppression that makes these drugs work is the same mechanism that can quietly starve muscle of the protein and total calories it needs to rebuild. Many people on a strong dose simply stop feeling hungry enough to eat the protein their muscle requires, and they do not notice the shortfall until strength or stamina slips. This is why the countermeasures below are not optional extras. They are the difference between losing mostly fat and giving away a meaningful share of muscle.

The simplest way to actually get this done

Superpower is a full-body lab membership that runs 100+ biomarkers, has each result reviewed by a doctor, and tracks your numbers year over year (about $199/year). It is what we point readers to when they would rather get one clean, complete draw than chase single tests one at a time. Here is superpower reviewed in full.

Check current Superpower pricing →

Why Muscle Loss Matters and Who Is Most at Risk

Skeletal muscle drives resting metabolic rate, glucose disposal, and functional independence. For younger adults with adequate lean mass reserves, losing a few kilograms of muscle during a major weight loss effort is unlikely to cause noticeable functional decline. For adults over 65, the math is less forgiving.

Natural aging already reduces skeletal muscle mass by roughly 12 to 16 percent, according to a 2024 Endocrine Society review. Half of adults over 80 have clinically significant sarcopenia, the term for low muscle mass and strength. An editorial in the Annals of Internal Medicine flagged that GLP-1 receptor agonists are being prescribed to older adults who may lack the reserve to absorb pharmacologically induced muscle losses without functional consequences. A study at ENDO 2025 added a metabolic dimension: semaglutide users who lost more muscle showed less improvement in HbA1c than those who preserved lean mass.

The Endocrine Society study also identified three characteristics linked to greater muscle loss after controlling for total weight lost: older age, female sex, and inadequate protein intake. Sedentary GLP-1 users face compounded risk because appetite suppression can reduce both total calories and protein intake simultaneously. For a broader look at adverse effects on this drug class, see our summary of Ozempic side effects.

Muscle also shapes what happens after the weight comes off. Lower muscle mass means a lower resting metabolic rate, which means fewer calories burned at rest and an easier path to regaining fat if eating rebounds. People who lose a large share of muscle during weight loss often find maintenance harder than expected, because they emerge lighter but with a slower engine. Protecting lean tissue on the way down is partly an investment in keeping the weight off later.

How Do You Know If You Are Losing Too Much Muscle?

You cannot feel muscle loss the way you feel a fever, so it helps to watch for concrete signals rather than wait for a problem to announce itself.

The most practical at-home marker is function. If stairs feel harder, if standing up from a low chair without using your hands becomes a struggle, if you tire faster carrying groceries, or if your balance feels less steady, those are signs that strength is slipping faster than it should. A simple benchmark clinicians use is the sit-to-stand test: rising from a chair five times without using your arms should take well under 15 seconds in a healthy adult. Grip strength, measured with an inexpensive hand dynamometer, is another proxy that tracks whole-body strength surprisingly well and takes seconds to check.

On the measurement side, a DEXA scan before starting and again after a few months is the cleanest way to separate fat loss from lean loss. Bioelectrical impedance scales are far less precise and are easily thrown off by hydration, but a consistent downward trend on the same scale under the same morning conditions can still flag a problem worth investigating. Ask your clinician about a baseline if you are older, sedentary, or already lean, because the people with the least muscle to spare are the ones who most need a number to track against.

Blood work adds a metabolic layer. The ENDO 2025 finding that semaglutide users who lost more muscle showed less improvement in HbA1c is a reminder that muscle is where much of your glucose gets disposed of. If your weight is dropping but your blood sugar, energy, or strength is not improving the way you expected, unaddressed muscle loss is one explanation worth ruling out with your prescriber.

How to Protect Muscle While on a GLP-1 Drug

Lean mass loss during GLP-1 treatment is not inevitable at levels that impair function. Two strategies have solid clinical backing.

Resistance Training

Resistance training is the most effective tool for preserving muscle during weight loss. A 6-month study of 200 adults who started semaglutide or tirzepatide alongside structured resistance exercise and protein guidance lost about 13 percent of body weight but only about 3 percent of muscle mass. That ratio is substantially better than what the STEP trials observed without structured exercise. Two to three sessions per week targeting major muscle groups is the evidence-based minimum; bodyweight training works when gym access is limited.

Adequate Protein Intake

The standard RDA of 0.8 g of protein per kg of body weight per day was set to prevent deficiency in sedentary adults, not to preserve muscle during weight loss. A 2022 systematic review and meta-analysis found that intakes of 1.2 to 1.6 g per kg per day preserved lean mass and strength during caloric restriction across age groups. Endocrine Society guidance now commonly targets at least 1.2 g per kg per day for GLP-1 users, with some clinicians recommending 1.5 g per kg for older adults.

Because these drugs suppress appetite substantially, protein intake can fall disproportionately if overall food volume drops. Distributing protein across three to four meals rather than eating the same total amount in one or two sittings is more effective for muscle protein synthesis. Working with a registered dietitian can help calibrate intake without triggering severe caloric restriction, which independently accelerates lean mass loss.

Hitting 1.2 g per kg is easier to act on when you picture it as food. For a 70 kg (about 154 lb) adult, that target is roughly 84 g of protein a day. A day that reaches it might look like three eggs and Greek yogurt at breakfast, a chicken breast or a can of tuna at lunch, a palm-sized portion of fish, beef, tofu, or lentils at dinner, and a protein shake or cottage cheese to close any gap. Each of those meals lands near 25 to 40 g of protein, which is the range that best triggers muscle protein synthesis in one sitting. Leucine, an amino acid concentrated in animal proteins, whey, and soy, is the main switch for that response, so plant-based eaters generally need slightly higher total intake and more deliberate variety to match it.

A realistic scenario shows how the pieces fit. Picture a 58-year-old woman starting semaglutide at 88 kg who feels almost no hunger by week eight. Left to drift, she settles into one small meal a day, loses weight fast, and notices her arms look thinner and her usual walk leaves her winded. The fix is not complicated. She sets a floor of about 100 g of protein a day spread over three small meals, adds two short resistance sessions with bands at home, and asks for a repeat body composition check at month four. The weight still comes off, but far more of it comes from fat, and her strength holds instead of fading.

Emerging Research: Bimagrumab Combinations

The pharmaceutical pipeline includes drug combinations designed to decouple fat loss from lean mass loss. The Phase 2b BELIEVE trial, published in Nature Medicine in 2026, tested bimagrumab (a monoclonal antibody that blocks muscle breakdown signaling) combined with semaglutide. The combination achieved 22.1 percent total weight loss over 72 weeks. Critically, 92.8 percent of that weight loss came from fat mass, compared to 71.8 percent in the semaglutide-alone group. Bimagrumab is not approved as of mid-2026, but the trial demonstrates that near-total fat-specific weight loss is biologically achievable.

For now, the practical message from this research is not to wait for a muscle-sparing pill. Bimagrumab and similar agents are years from routine use, and access, cost, and long-term safety are all still open questions. The tools that already work, lifting and eating enough protein, are free and available today, and they are exactly what the drug pipeline is trying to reproduce. Anyone starting a GLP-1 drug this year is better off treating resistance training and protein as part of the prescription rather than something to consider later.

Actionable Steps: Protecting Lean Mass on GLP-1 Treatment

  1. Start resistance training at the same time as the medication, not after lean mass loss has already occurred. Two to three sessions per week is the minimum.
  2. Track daily protein explicitly. Aim for at least 1.2 g per kg of body weight. A one-week food log establishes your baseline.
  3. Spread protein across three to four meals. Muscle protein synthesis responds better to distributed intake than to one large protein dose per day.
  4. Do not over-restrict calories. If nausea limits eating, prioritize protein-dense foods first when appetite returns. Severe restriction accelerates muscle loss independently of protein percentage.
  5. Request a baseline assessment if you are over 55 or have a history of low physical activity. A starting measure of muscle mass or grip strength gives you a benchmark for monitoring during treatment.

Frequently Asked Questions

Do GLP-1 drugs like semaglutide cause muscle loss?

Yes, some lean mass loss is expected with any significant weight loss, and GLP-1 drugs are no exception. The STEP 1 DEXA substudy found lean body mass declined about 9.7 percent in absolute terms over 68 weeks on semaglutide 2.4 mg. Fat mass fell faster at 19.3 percent, so the body composition ratio improved. The concern centers on the absolute amount of muscle lost, particularly for older adults with less reserve.

How much of weight lost on a GLP-1 drug is actually muscle?

A 2024 review in Diabetes, Obesity and Metabolism found lean mass loss accounted for roughly 25 percent of total weight lost across GLP-1 receptor agonist trials on average. Individual study figures range from 15 to 40 percent depending on patient age, baseline muscle mass, protein intake, and exercise habits during treatment.

Is GLP-1 muscle loss worse than muscle loss from regular dieting?

Not in percentage terms. Standard diet-only interventions also lose 20 to 30 percent of weight from lean tissue. GLP-1 therapies fall in a comparable range. The difference is the larger total weight loss these drugs achieve, which means the absolute pounds of muscle lost can be higher even if the proportion is similar.

What can I do to protect muscle while taking a GLP-1 medication?

Resistance training two to three times per week and consuming at least 1.2 g of protein per kg of body weight per day are the two best-supported strategies. A 6-month study presented at ENDO 2025 found that adults who received guidance on both at the start of semaglutide or tirzepatide treatment lost about 13 percent of body weight but only about 3 percent of muscle mass. Always discuss diet and exercise changes with your prescribing clinician before making them.

Can you build muscle while losing weight on a GLP-1 drug?

It is possible but hard, and it is most realistic for people who are new to resistance training or returning after a long layoff. In a large calorie deficit with suppressed appetite, the body has little surplus to build new tissue, so the honest goal for most people is to preserve the muscle they already have rather than add to it. Beginners and those with higher body fat have the best odds of the recomposition effect, where fat falls while muscle holds or edges up, provided they train consistently and hit their protein target. Experienced lifters are usually better served by holding steady during the weight loss phase and building afterward.

Will I get the muscle back after stopping the medication?

Muscle responds to demand, so lean mass can be rebuilt with resistance training and adequate protein after treatment ends, the same way it is built at any other time. The catch is that many people regain fat quickly once appetite returns if they stop the drug without a maintenance plan, and regained weight tends to come back as fat more than as muscle. Keeping the training and protein habits in place through and after the transition is what protects the body composition you worked for.

Does tirzepatide cause more muscle loss than semaglutide?

Both drugs produce lean mass loss roughly in proportion to how much total weight they remove, and tirzepatide tends to drive larger total weight loss, so the absolute lean mass lost can be higher even when the proportion is similar. Direct head-to-head body composition comparisons are still limited, so the safest reading of current evidence is that the countermeasures matter more than the specific molecule. Resistance training and adequate protein protect muscle on either drug.

Want a real clinician to run the numbers, not a guess?

Joi + Blokes is a telehealth clinic that prescribes GLP-1 medication (Zepbound, compounded semaglutide and tirzepatide), hormone therapy (TRT, HRT), thyroid care, and peptides after a real lab panel and clinician review, with no membership or consult fee (prescriptions from about $59/month, lab panels from $149). If the scale will not budge, this is where you find out whether insulin, thyroid, or hormones are the real reason. Here is Joi + Blokes reviewed in full.

See Joi + Blokes pricing →

Sources

  • Wadden TA, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021. PMC8089287.
  • Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024. PubMed 38937282.
  • Haines MS. Protein intake and muscle loss in semaglutide users. Presented at ENDO 2025; Endocrine Society Annual Meeting.
  • Bimagrumab + Semaglutide BELIEVE trial. Nature Medicine. 2026. Via EurekAlert.
  • Morton RW, et al. Systematic review and meta-analysis of protein intake to support muscle mass and function in healthy adults. Nutr Rev. 2022. PMC8978023.

Sources